Comparison of transarterial embolisation (TAE) or chemoembolisation (TACE) using streptozotocin (STZ) and biomarker study in patients with metastatic neuroendocrine tumors (NET)

#3954

Introduction: We compared TACE and TAE in patients with pancreatic (pNET) or small-intestine NET (siNET) and explored the role of biomarkers related to alkylating agents (O6-methylguanine-methyltransferase [MGMT], alkylpurine–DNA–N-glycosylase [APNG]) or hypoxia (Carbonic anhydrase IX [CAIX]).

Aim(s): The primary endpoints were ORR and progression-free survival (PFS).

Materials and methods: We studied all patients with metastatic pNET of siNET treated between 2006 and 2020 in one expert centre with the same protocol of liver TAE preceded or not by STZ injection (1500 mg/m2). We centrally reviewed clinical data, RECIST-defined objective response rate [ORR] and tumor immunostaining (H-score [0-300] of MGMT, APNG and CAIX).

Conference:

Presenting Author: de Mestier L

Authors: Vedie A, Dioguardii Burgioo M, Matteini F, Akez M, Hentic O,

Keywords: transarterial embolization, chemoembolization, metastatic neuroendocrine tumor, biomarker,